Supplementary Materials

Supplementary Material for:

Deglycosylated bleomycin has the antitumor activity of bleomycin without pulmonary toxicity

Olivier Burgy, Guillaume Wettstein, Pierre S. Bellaye, Nathalie Decologne, Cindy Racoeur, Fran├žoise Goirand, Guillaume Beltramo, Jean-Fran├žois Hernandez, Abderraouf Kenani, Philippe Camus, Ali Bettaieb, Carmen Garrido, Philippe Bonniaud*

*Corresponding author. E-mail: philippe.bonniaud{at}chu-dijon.fr

Published 17 February 2016, Sci. Transl. Med. 8, 326ra20 (2016)
DOI: 10.1126/scitranslmed.aad7785

This PDF file includes:

  • Fig. S1. Deglyco-BLM has the same antitumoral profile as BLM but lacks toxic side effects.
  • Fig. S2. BLM, but not deglyco-BLM, induces lung toxicity.
  • Fig. S3. BLM, but not deglyco-BLM, induces collagen accumulation in the lung.
  • Fig. S4. Deglyco-BLM does not induce inflammation and fibrosis-related cytokines.
  • Fig. S5. Deglyco-BLM and BLM do not induce nitrogen species or ER stress in A549 cells.
  • Fig. S6. BLM induces caspase-1 activation in alveolar epithelial cells but not in immune cells.
  • Fig. S7. Deglyco-BLM and BLM induce similar caspase-3 cleavage.

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Table S1 Original data (provided as a separate Excel file).